

Title (en)
THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR

Title (de)
THERAPEUTISCHE VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS UNTER VERWENDUNG VON 6,8-BIS-BENZYLTHIO-OCTANSÄURE UND EINEM AUTOPHAGEN INHIBITOR

Title (fr)
COMPOSITIONS ET MÉTHODES THÉRAPEUTIQUES POUR TRAITER LE CANCER FAISANT APPEL À L'ACIDE 6,8-BIS-BENZYLTHIO-OCTANOÏQUE ET À UN INHIBITEUR D'AUTOPHAGIE

Publication
EP 3897607 A4 20220824 (EN)

Application
EP 19901283 A 20191220

Priority

- US 201862782928 P 20181220
- US 201962793667 P 20190117
- US 201962834475 P 20190416
- US 201962854599 P 20190530
- US 2019067759 W 20191220

Abstract (en)
[origin: WO2020132397A1] The invention provides methods and compositions for treating cancer by administering to a patient in need thereof a therapeutically effective amount of 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.

IPC 8 full level
A61K 31/20 (2006.01); **A61K 31/155** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/4706** (2006.01); **A61K 31/7004** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01)

CPC (source: AU EP KR)
A61K 31/155 (2013.01 - AU EP); **A61K 31/192** (2013.01 - EP KR); **A61K 31/20** (2013.01 - AU EP); **A61K 31/365** (2013.01 - AU); **A61K 31/4184** (2013.01 - EP KR); **A61K 31/4706** (2013.01 - AU EP KR); **A61K 31/52** (2013.01 - AU); **A61K 31/7004** (2013.01 - AU EP); **A61K 45/06** (2013.01 - EP); **A61P 35/00** (2018.01 - AU EP KR); **A61P 35/02** (2018.01 - EP); **A61K 2300/00** (2013.01 - AU KR)

C-Set (source: AU EP)
AU

1. **A61K 31/20 + A61K 2300/00**
2. **A61K 31/7004 + A61K 2300/00**
3. **A61K 31/52 + A61K 2300/00**
4. **A61K 31/4706 + A61K 2300/00**
5. **A61K 31/365 + A61K 2300/00**
6. **A61K 31/155 + A61K 2300/00**

EP

1. **A61K 31/4706 + A61K 2300/00**
2. **A61K 31/20 + A61K 2300/00**
3. **A61K 31/192 + A61K 2300/00**
4. **A61K 31/155 + A61K 2300/00**
5. **A61K 31/7004 + A61K 2300/00**
6. **A61K 31/4184 + A61K 2300/00**

Citation (search report)

- [XY] REBECCA ANDERSON BS ET AL: "PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613", HEMASPHERE, 1 June 2018 (2018-06-01), XP055722056, Retrieved from the Internet <URL:https://rafaelpharma.com/wp-content/uploads/2018/07/Rafael-Abstract-EHA-2018-Poster-AML_Aging.pdf> [retrieved on 20200812]
- [Y] ANONYMOUS: "Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma", BLOOD, 1 January 2016 (2016-01-01), XP055741754, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/128/22/4163/114147/Phase-I-Dose-Escalation-Study-of-Cpi-613-in> [retrieved on 20201020]
- [Y] ZUZANA ZACHAR ET AL: "Non-redox-active lipoate derivatives disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 89, no. 11, 19 July 2011 (2011-07-19), pages 1137 - 1148, XP019965329, ISSN: 1432-1440, DOI: 10.1007/S00109-011-0785-8
- [Y] KING C LEE ET AL: "Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613", ANNALS OF TRANSLATIONAL MEDICINE, 1 September 2014 (2014-09-01), China, pages 91 - 1014, XP055679530, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205874/pdf/atm-02-09-91.pdf> [retrieved on 20200325], DOI: 10.3978/j.issn.2305-5839.2014.05.08
- [Y] T. S. PARDEE ET AL: "A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies", CLINICAL CANCER RESEARCH, vol. 20, no. 20, 27 August 2014 (2014-08-27), US, pages 5255 - 5264, XP055721419, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-1019
- [A] ANGELIQUE V ONORATI ET AL: "Targeting autophagy in cancer", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 124, no. 16, 19 April 2018 (2018-04-19), pages 3307 - 3318, XP071177994, ISSN: 0008-543X, DOI: 10.1002/CNCR.31335
- [A] PASQUIER BENOIT: "Autophagy inhibitors", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 73, no. 5, 11 December 2015 (2015-12-11), pages 985 - 1001, XP035801809, ISSN: 1420-682X, [retrieved on 20151211], DOI: 10.1007/S00018-015-2104-Y
- See also references of WO 2020132397A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2020132397 A1 20200625; AU 2019404339 A1 20210624; CA 3121929 A1 20200625; CN 113543778 A 20211022;
EP 3897607 A1 20211027; EP 3897607 A4 20220824; JP 2022515171 A 20220217; KR 20210105923 A 20210827; TW 202038931 A 20201101

DOCDB simple family (application)

US 2019067759 W 20191220; AU 2019404339 A 20191220; CA 3121929 A 20191220; CN 201980084130 A 20191220;
EP 19901283 A 20191220; JP 2021535902 A 20191220; KR 20217021086 A 20191220; TW 108147080 A 20191220